Get the Stockscreener App
0.6737
4.77%
0.0307
Tiziana Life Sciences Ltd stock is traded at $0.6737, with a volume of 193.29K.
It is up +4.77% in the last 24 hours and down -4.24% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$0.643
Open:
$0.658
24h Volume:
193.29K
Relative Volume:
0.34
Market Cap:
$66.76M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-5.1823
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
-1.65%
1M Performance:
-4.24%
6M Performance:
-51.88%
1Y Performance:
+31.71%
1-Day Range:
$0.6333
$0.6853
1-Week Range:
$0.6302
$0.6961
52-Week Range:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.6737 | 66.76M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
Tiziana Life Sciences Faces Nasdaq Compliance Challenge - MSN
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4% - Defense World
Tiziana Life Sciences (FRA:0RP) Total Liabilities : €8.46 Mil (As of Jun. 2024) - GuruFocus.com
Tiziana Life Sciences Ltd (NASDAQ: TLSA) Jumps 11.06%: What Could Be On The Way Going Forward? - Stocks Register
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 - The Manila Times
Tiziana reports progress in spinal cord injury treatment - MSN
Tiziana reports progress in spinal cord injury treatment By Investing.com - Investing.com Australia
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury - Proactive financial news
Tiziana's Nasal Treatment Shows Promise for Spinal Cord Injury Recovery in Breakthrough Study - StockTitan
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study - Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future - The Manila Times
Tiziana Life Sciences Halts Capital Raising Plans After Promising MS Treatment Biomarker Discovery - StockTitan
Tiziana Life Sciences pauses capital raising activities - Proactive Investors USA
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab - Proactive Investors UK
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab - The Manila Times
Tiziana Life Sciences Reveals Breakthrough Biomarkers in Multiple Sclerosis Treatment Study - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive financial news
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
Sanctuary Advisors LLC Makes New $864,000 Investment in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - MarketBeat
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tiziana broadens Phase 2 trial for MS therapy - Investing.com India
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):